BANCROFT FUND LTD Form N-Q September 24, 2010

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

FORM N-Q

QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY

Investment Company Act file number: 811-02151

Bancroft Fund Ltd.

\_\_\_\_\_

(Exact name of registrant as specified in charter)

65 Madison Avenue, Morristown, New Jersey 07960-7308

-----

(Address of principal executive offices) (Zip code)

Thomas H. Dinsmore
Bancroft Fund Ltd.
65 Madison Avenue
Morristown, New Jersey 07960-7308
(Name and address of agent for service)

Copy to: Steven B. King, Esq. Ballard Spahr LLP 1735 Market Street, 51st Floor Philadelphia, PA 19103-7599

Registrant's telephone number, including area code: 973-631-1177

Date of fiscal year end: October 31, 2010

Date of reporting period: July 31, 2010

## ITEM 1. SCHEDULE OF INVESTMENTS.

## Bancroft Fund Ltd. Schedule of Investments

**July 31, 2010** (Unaudited)

Countral European Distribution Corp. 3%, due 2013 ev. sr. notes (B-)   1,000,000   886,250		Principal Amount	Value
Central European Distribution Corp. 3%, due 2013 cv. sr. notes (B-)   1,000,000   886,250		Amount	(Note 1)
Central European Distribution Corp. 3%, due 2013 cv. sr. notes (B-)   1,000,000   886,250	Foods - 0.9%		0,011,505
Charles River Laboratories Int'l, Inc. 2.25%, due 2013 cv sr notes (BB+)		1,000,000	886,250
China Medical Technologies, Inc. 4%, due 2013 cv. sr. sub. notes (NR)	Healthcare - 8.4%		
(exchangeable for ADS representing common stock)         1,500,000         991,875           Greatbatch, Inc. 2,25%, due 2013 cv. sub. deb. (NR)         1,500,000         1,385,625           Integra LifeSciences Holdings, 2,375%, due 2012 cv. sr. notes (NR)         1,007,000         1,616,250           Kinetic Concepts, Inc. 3,25%, due 2014 cv. sub. notes (B)         1,000,000         950,000           SonoSite Inc. 3,75%, due 2014 cv. sr. notes (NR)         1,000,000         950,000           SonoSite Inc. 3,75%, due 2014 cv. sr. notes (NR)         1,000,000         942,500           Kaiser Aluminum Corp. 4,5%, due 2015 cash cv. sr. notes (NR)         1,000,000         942,500           Kaiser Aluminum Corp. 4,5%, due 2014 cv. sr. notes (Ba2)         250,000         390,938           Zal15,638         2,415,638           Multi-Industry - 1,3%         LSB Industries, Inc. 5,5%, due 2012 cv. sr. sub. deb. (NR)         1,250,000         1,256,250           Pharmaceuticals - 9,6%           Amylin Pharmaceutical, Inc. 3%, due 2014 cv. sr. notes (NR)         1,000,000         1,018,750           Gilead Sciences, Inc. 0,5%, due 2011 cv. sr. notes (NR)         1,000,000         1,018,750           Gilead Sciences, Inc. 0,5%, due 2011 cv. sr. notes (NR)         500,000         249,844           Gilead Sciences, Inc. 1,6, due 2014 cv. sr. notes (NR)         250,000         249,844<	Charles River Laboratories Int'l, Inc. 2.25%, due 2013 cv sr notes (BB+)	1,000,000	957,500
Greatbatch, Inc. 2.25%, due 2013 cv. sub. deb. (NR) (3)   1,500,000   1,385,625   Integra LifeSciences Holdings, 2.375%, due 2012 cv. sr. notes (NR)   1,067,000   1,010,983   Kinetic Concepts, Inc. 3.25%, due 2015 cv. sr. notes (BB-)   1,000,000   1,466,225   LifePoint Hospitals Inc. 3.5%, due 2014 cv. sub. notes (BB)   1,000,000   1,003,750   7,815,983   1,000,000   1,003,750   Metals and Mining - 2.6%   1,000,000   1,003,750   Metals and Mining - 2.6%   1,000,000   1,003,750   Mayaur Mining, Inc. 4.5%, due 2014 cv. sr. notes (NR)   1,000,000   942,500   Kaiser Aluminum Corp. 4.5%, due 2015 cash cv. sr. notes (NR) (2)   1,000,000   1,082,200   Multi-Industry - 1.3%   1,250,000   1,256,250    Pharmaceuticals - 9.6%   1,250,000   1,256,250    Pharmaceuticals - 9.6%   2,250,000   1,256,250    Pharmaceuticals - 9.6%   2,250,000   1,000,000   1,018,750   Gilead Sciences, Inc. 0.5%, due 2014 cv. sr. sub. notes (NR)   1,000,000   1,018,750   Gilead Sciences, Inc. 0.5%, due 2014 cv. sr. notes (NR)   1,000,000   1,018,750   Gilead Sciences, Inc. 0.5%, due 2014 cv. sr. notes (NR)   2,000,000   1,018,750   Gilead Sciences, Inc. 0.5%, due 2014 cv. sr. notes (NR)   3,000,000   1,018,750   Gilead Sciences, Inc. 1.5%, due 2016 cv. sr. notes (NR)   3,000,000   249,844   Gilead Sciences, Inc. 0.55%, due 2016 cv. sr. notes (NR)   3,000,000   249,844   Gilead Sciences, Inc. 1.55%, due 2016 cv. sr. notes (NR)   3,000,000   3,000,000   Gilead Sciences, Inc. 1.55%, due 2016 cv. sr. notes (NR)   3,000,000   3,000,000   Gilead Sciences, Inc. 1.55%, due 2016 cv. sr. notes (NR)   3,000,000   3,000,000   Gilead Sciences, Inc. 1.55%, due 2016 cv. sr. notes (NR)   3,000,000   3,000,000   Gilead Sciences, Inc. 1.55%, due 2016 cv. sr. notes (NR)   3,000,000   3,000,000   Gilead Sciences, Inc. 1.55%, due 2016 cv. sr. notes (NR)   3,000,000   3,000,000   Gilead Sciences, Inc. 1.55%, due 2016 cv. sr. notes (NR)   3,000,000   3,000,000   Gilead Sciences, Inc. 1.55%, due 2016 cv. sr. notes (NR)   3,000,000   3,000,000   Gilead Sciences, Inc. 1			
Integra LifeSciences Holdings, 2.375%, due 2012 cv. sr. notes (NR)   1,067,000   1,010,983     Kinetic Concepts, Inc. 3.25%, due 2015 cv. sr. notes (BB-)   1,500,000   1,606,250     LifePoint Hospitals Inc. 3.5%, due 2014 cv. sr. notes (NR)   1,000,000   950,000     SonoSite Inc. 3.75%, due 2014 cv. sr. notes (NR)   1,000,000   1,053,750     Raiser Aluminum Corp. 4.5%, due 2015 cash cv. sr. notes (NR)   1,000,000   1,082,200     Maiser Aluminum Corp. 4.5%, due 2015 cash cv. sr. notes (NR) (2)   1,000,000   1,082,200     United States Steel Corp. 4%, due 2014 cv. sr. notes (Ba2)   250,000   390,938     LSB Industries, Inc. 5.5%, due 2012 cv. sr. sub. deb. (NR)   1,250,000   1,256,250     Pharmaceuticals - 9.6%   1,250,000   1,256,250     Pharmaceuticals - 9.6%   1,000,000   871,250     Cephalon, Inc. 2.5%, due 2014 cv. sr. notes (NR)   1,000,000   1,018,750     Gilead Sciences, Inc. 0.5%, due 2011 cv. sr. notes (NR)   1,000,000   1,018,750     Gilead Sciences, Inc. 1,25%, due 2011 cv. sr. notes (NR)   500,000   510,000     Gilead Sciences, Inc. 1,25%, due 2014 cv. sr. notes (NR) (2)   250,000   249,844     Gilead Sciences, Inc. 1,625%, due 2016 cv. sr. notes (NR) (2)   375,000   375,234     Millipore Corp. 3,75%, due 2026 cv. sr. notes (NR) (2)   375,000   375,234     Millipore Corp. 3,75%, due 2026 cv. sr. notes (NR) (2)   375,000   375,234     Millipore Corp. 3,75%, due 2026 cv. sr. notes (NR) (2)   375,000   375,234     Millipore Corp. 3,75%, due 2026 cv. sr. notes (NR) (2)   375,000   375,234     Millipore Corp. 3,75%, due 2026 cv. sr. notes (NR) (2)   375,000   375,234     Millipore Corp. 3,75%, due 2026 cv. sr. notes (NR) (2)   375,000   375,234     Millipore Corp. 3,75%, due 2026 cv. sr. notes (NR) (2)   375,000   375,234     Millipore Corp. 3,75%, due 2026 cv. sr. notes (NR) (2)   375,000   375,234     Millipore Corp. 3,75%, due 2026 cv. sr. notes (NR) (2)   375,000   375,235     Manaly Capital Management, Inc. 4%, due 2015 cv. sr. notes (NR) (2)   375,000   375,237     Teva Pharmaceutical Finance Co.	, c	1,500,000	991,875
Kinetic Concepts, Inc. 3.25%, due 2015 cv. sr. notes (BB-) 1,500,000 1,466,250 LifePoint Hospitals Inc. 3.5%, due 2014 cv. sub. notes (B) 1,000,000 500,000 SonoSite Inc. 3.75%, due 2014 cv. sr. notes (NR) 1,000,000 1,53,750 7,815,983  Metals and Mining - 2.6% Jaguar Mining, Inc. 4.5%, due 2014 cv. sr. notes (NR) 1,000,000 942,500 Kaiser Aluminum Corp. 4.5%, due 2015 cash cv. sr. notes (NR) (2) 1,000,000 1,082,200 United States Steel Corp. 4%, due 2014 cv. sr. notes (Ba2) 250,000 390,938  Multi-Industry - 1.3% LSB Industries, Inc. 5.5%, due 2012 cv. sr. sub. deb. (NR) 1,250,000 1,256,250  Pharmaceuticals - 9.6% Amylin Pharmaceutical, Inc. 3%, due 2014 cv. sr. notes (NR) 1,000,000 1,073,750 Endo Pharmaceuticals Holdings, Inc. 1.75%, due 2015 cv. sr. sub. notes (NR) 1,000,000 1,018,750 Gilead Sciences, Inc. 0.5%, due 2014 cv. sr. notes (NR) 500,000 249,844 Gilead Sciences, Inc. 1.625%, due 2016 cv. sr. notes (NR) (2) 375,000 375,234 Millipore Corp. 3.75%, due 2026 cv. sr. notes (BB-) (3) 750,000 950,625 Mylan Laboratories, Inc. 1.25%, due 2012 cv. sr. notes (BB-) (convertible into Mylan Inc. common stock) 1,500,000 759,375 Teva Pharmaceutical Finance Co. B. V. 1.75%, due 2026 cv. sr. deb. (A3) (exchangeable for Teva Pharmaceutical Industries Ltd. ADR) 1,500,000 1,681,875 Polital Management, Inc. 4%, due 2016 cv. sr. notes (NR) (2) 500,000 2,825,825,188  Real Estate - 3.0% Annaly Capital Management, Inc. 4%, due 2015 cv. sr. notes (NR) (2) 500,000 2,852,188  Semiconductors - 2.5% Intel Corp. 2.95%, due 2039 jr. sub. cv. deb. (A-) (3) 1,000,000 1,011,000 Xilinx, Inc. 2.625%, due 2017 cv. sr. notes (BB-) (2) 250,000 275,938 Intel Corp. 3.25%, due 2017 cv. sr. notes (BB-) (2) 250,000 275,938 Intel Corp. 2.95%, due 2017 cv. sr. notes (BB-) (2) 250,000 275,938 Intel Corp. 3.25%, due 2017 cv. sr. notes (BB-) (2) 250,000 275,938 Intel Corp. 2.95%, due 2039 jr. sub. cv. deb. (A-) (3) 1,000,000 1,071,000 275,938			
LifePoint Hospitals Inc. 3.5%, due 2014 cv. sub. notes (B) 1,000,000 1,003,750 7,815,983  Metals and Mining - 2.6%  Jaguar Mining, Inc. 4.5%, due 2014 cv. sr. notes (NR) 1,000,000 942,500 Maiser Aluminum Corp. 4.5%, due 2015 cash cv. sr. notes (NR) 1,000,000 942,500 1,002,000 United States Steel Corp. 4%, due 2014 cv. sr. notes (Ba2) 250,000 390,938 2,415,638  Multi-Industry - 1.3% LSB Industries, Inc. 5.5%, due 2012 cv. sr. sub. deb. (NR) 1,250,000 1,256,250  Pharmaceuticals - 9.6% Amylin Pharmaceutical, Inc. 3%, due 2014 cv. sr. notes (NR) 1,000,000 1,073,750 Endo Pharmaceuticals Holdings, Inc. 1.75%, due 2015 cv. sr. sub. notes (NR) 1,000,000 1,018,750 Gilead Sciences, Inc. 1.6,5%, due 2014 cv. sr. notes (NR) 500,000 510,000 510,000 Gilead Sciences, Inc. 1.625%, due 2014 cv. sr. notes (NR) 250,000 249,844 Gilead Sciences, Inc. 1.625%, due 2016 cv. sr. notes (NR) 250,000 249,844 Gilead Sciences, Inc. 1.625%, due 2016 cv. sr. notes (NR) 750,000 950,625 Mylan Laboratories, Inc. 1.25%, due 2016 cv. sr. notes (NR) 1,500,000 1,522,500 Onyx Pharmaceuticals, Inc. 4%, due 2016 cv. sr. notes (NR) 750,000 759,375 Teva Pharmaceutical Finance Co. B.V. 1.75%, due 2026 cv. sr. deb. (A3) (exchangeable for Teva Pharmaceutical Industries Ltd. ADR) 1,500,000 1,681,875 9,013,203 Real Estate - 3.0% Annaly Capital Management, Inc. 4%, due 2015 cv. sr. notes (NR) 1,500,000 1,681,875 9,013,203 Real Estate - 3.0% Annaly Capital Management, Inc. 4%, due 2015 cv. sr. notes (NR) 2 500,000 2,000,000 Lexington Realty Trust 6%, due 2030 cv. guaranteed notes (NR) 1,000,000 1,041,250 2,852,188 Semiconductors - 2.5% due 2030 cv. guaranteed notes (NR) 2 500,000 2,000,000 1,071,000 2,75,938 due 2035 jr. sub. cv. deb. (A-) 3 1,000,000 1,071,000 2,75,938 due 2035 jr. sub. cv. deb. (A-) 3 1,000,000 2,75,938 1,843,188 Telecommunications - 14.1%		1,067,000	1,010,983
SonoSite Inc. 3.75%, due 2014 cv. sr. notes (NR)	•	1,500,000	1,466,250
Metals and Mining - 2.6%           Jaguar Mining, Inc. 4.5%, due 2014 cv. sr. notes (NR)         1,000,000         942,500           Kaiser Aluminum Corp. 4.5%, due 2015 cash cv. sr. notes (NR) (2)         1,000,000         1,082,200           United States Steel Corp. 4%, due 2014 cv. sr. notes (Ba2)         250,000         390,938           2,415,638           Multi-Industry - 1.3%         LSB Industries, Inc. 5.5%, due 2012 cv. sr. sub. deb. (NR)         1,250,000         1,256,250           Pharmaceuticals - 9.6%           Amylin Pharmaceutical, Inc. 3%, due 2014 cv. sr. notes (NR)         1,000,000         871,250           Cephalon, Inc. 2.5%, due 2014 cv. sr. sub. notes (NR)         1,000,000         1,018,750           Endo Pharmaceuticals Holdings, Inc. 1.75%, due 2015 cv. sr. sub. notes (NR)         1,000,000         1,018,750           Gilead Sciences, Inc. 0.5%, due 2014 cv. sr. notes (NR)         500,000         510,000           Gilead Sciences, Inc. 1.625%, due 2016 cv. sr. notes (NR) (2)         375,000         375,234           Millipore Corp. 3.75%, due 2026 cv. sr. notes (NB) (2)         375,000         375,234           Mylan Laboratories, Inc. 1.25%, due 2012 cv. sr. notes (BB-)         1,500,000         1,522,500           Onyx Pharmaceuticals, Inc. 4%, due 2016 cv. sr. notes (NR)         750,000         759,375           Teva Pharmaceutica	LifePoint Hospitals Inc. 3.5%, due 2014 cv. sub. notes (B)	1,000,000	950,000
Metals and Mining - 2.6%           Jaguar Mining, Inc. 4.5%, due 2014 cv. sr. notes (NR)         1,000,000         1,082,200           Kaiser Aluminum Corp. 4.5%, due 2015 cash cv. sr. notes (NR) (2)         1,000,000         1,082,200           United States Steel Corp. 4%, due 2014 cv. sr. notes (Ba2)         250,000         390,938           Multi-Industry - 1.3%         LSB Industries, Inc. 5.5%, due 2012 cv. sr. sub. deb. (NR)         1,250,000         1,256,250           Pharmaceuticals - 9.6%           Amylin Pharmaceutical, Inc. 3%, due 2014 cv. sr. notes (NR)         1,000,000         871,250           Cephalon, Inc. 2.5%, due 2014 cv. sr. sub. notes (NR)         1,000,000         1,018,750           Gilead Sciences, Inc. 0.5%, due 2011 cv. sr. notes (NR)         500,000         510,000           Gilead Sciences, Inc. 1%, due 2014 cv. sr. notes (NR) (2)         250,000         249,844           Gilead Sciences, Inc. 1.625%, due 2016 cv. sr. notes (NR) (2)         375,000         375,234           Millipore Corp. 3.75%, due 2026 cv. sr. notes (BB-) (3)         750,000         750,002           Mylan Laboratories, Inc. 1.25%, due 2012 cv. sr. notes (BB-)         1,500,000         1,522,500           Onyx Pharmaceutical Finance Co. B.V. 1.75%, due 2026 cv. sr. deb. (A3)         (exchangeable for Teva Pharmaceutical Industries Ltd. ADR)         1,500,000         1,681,875	SonoSite Inc. 3.75%, due 2014 cv. sr. notes (NR)	1,000,000	1,053,750
Jaguar Mining, Inc. 4.5%, due 2014 cv. sr. notes (NR)   1,000,000   1,082,200			7,815,983
Kaiser Aluminum Corp. 4.5%, due 2015 cash cv. sr. notes (NR) (2) 1,000,000 1,082,200 United States Steel Corp. 4%, due 2014 cv. sr. notes (Ba2) 250,000 390,938 2,415,638   Multi-Industry - 1.3%			
United States Steel Corp. 4%, due 2014 cv. sr. notes (Ba2)  2,415,638  Multi-Industry - 1.3%  LSB Industries, Inc. 5.5%, due 2012 cv. sr. sub. deb. (NR)  1,250,000  1,256,250  Pharmaceuticals - 9.6%  Amylin Pharmaceutical, Inc. 3%, due 2014 cv. sr. notes (NR)  Cephalon, Inc. 2.5%, due 2014 cv. sr. sub. notes (NR)  I,000,000  1,018,750  Gilead Sciences, Inc. 0.5%, due 2011 cv. sr. notes (NR)  Gilead Sciences, Inc. 1.6, due 2014 cv. sr. notes (NR)  Gilead Sciences, Inc. 1.6, due 2014 cv. sr. notes (NR)  Millipore Corp. 3.75%, due 2016 cv. sr. notes (NR) (2)  Convertible into Mylan Inc. common stock)  Onyx Pharmaceuticals, Inc. 4%, due 2016 cv. sr. notes (BB-)  (convertible into Mylan Inc. common stock)  Onyx Pharmaceutical Finance Co. B.V. 1.75%, due 2026 cv. sr. deb. (A3)  (exchangeable for Teva Pharmaceutical Industries Ltd. ADR)  Annaly Capital Management, Inc. 4%, due 2015 cv. sr. notes (NR) (2)  Real Estate - 3.0%  Annaly Capital Management, Inc. 4%, due 2015 cv. sr. notes (NR) (2)  Lexington Realty Trust 6%, due 2030 cv. guaranteed notes (NR) (2)  Soundon 1,000,000  Lexington Realty Trust 6%, due 2030 cv. guaranteed notes (NR) (2)  Intel Corp. 2.95%, due 2035 jr. sub. cv. deb. (A-) (3)  Intel Corp. 3.25%, due 2037 cv. sr. notes (BB-) (2)  Ze50,000  250,000  1,018,750  250,000  1,000  1,018,750  375,000  375,234  375,000  375,000  375,234  375,000  375,000  375,000  375,235  375,000  375,000  375,000  375,000  375,375  Teva Pharmaceutical Finance Co. B.V. 1.75%, due 2026 cv. sr. deb. (A3)  (exchangeable for Teva Pharmaceutical Industries Ltd. ADR)  1,500,000  1,681,875  9,013,203  Real Estate - 3.0%  Annaly Capital Management, Inc. 4%, due 2015 cv. sr. notes (NR) (2)  2,00,000  1,000,000  1,018,750  3,10,000  1,000,000  1,000,000  1,000,000			,
Multi-Industry - 1.3%	•		
Multi-Industry - 1.3%   LSB Industries, Inc. 5.5%, due 2012 cv. sr. sub. deb. (NR)   1,250,000   1,256,250	United States Steel Corp. 4%, due 2014 cv. sr. notes (Ba2)	250,000	
LSB Industries, Inc. 5.5%, due 2012 cv. sr. sub. deb. (NR)			2,415,638
Pharmaceuticals - 9.6%           Amylin Pharmaceutical, Inc. 3%, due 2014 cv. sr. notes (NR)         1,000,000         871,250           Cephalon, Inc. 2.5%, due 2014 cv. sr. sub. notes (NR)         1,000,000         1,073,750           Endo Pharmaceuticals Holdings, Inc. 1.75%, due 2015 cv. sr. sub. notes (NR)         1,000,000         1,018,750           Gilead Sciences, Inc. 0.5%, due 2011 cv. sr. notes (NR)         500,000         510,000           Gilead Sciences, Inc. 1.6, due 2014 cv. sr. notes (NR) (2)         250,000         249,844           Gilead Sciences, Inc. 1.625%, due 2016 cv. sr. notes (NR) (2)         375,000         375,234           Millipore Corp. 3.75%, due 2026 cv. sr. notes (BB-) (3)         750,000         950,625           Mylan Laboratories, Inc. 1.25%, due 2012 cv. sr. notes (BB-)         (convertible into Mylan Inc. common stock)         1,500,000         1,522,500           Onyx Pharmaceuticals, Inc. 4%, due 2016 cv. sr. notes (NR)         750,000         759,375           Teva Pharmaceutical Finance Co. B.V. 1.75%, due 2026 cv. sr. deb. (A3)         (exchangeable for Teva Pharmaceutical Industries Ltd. ADR)         1,500,000         1,681,875           Real Estate - 3.0%         Annaly Capital Management, Inc. 4%, due 2015 cv. sr. notes (NR)         1,250,000         1,310,938           Corporate Office Properties, L.P. 4.25% due 2030 exch. sr. notes (NR)         1,000,000         1,041,250     <			
Amylin Pharmaceutical, Inc. 3%, due 2014 cv. sr. notes (NR) 1,000,000 1,073,750 Cephalon, Inc. 2.5%, due 2014 cv. sr. sub. notes (NR) 1,000,000 1,073,750 Endo Pharmaceuticals Holdings, Inc. 1.75%, due 2015 cv. sr. sub. notes (NR) 1,000,000 1,018,750 Gilead Sciences, Inc. 0.5%, due 2011 cv. sr. notes (NR) 500,000 510,000 Gilead Sciences, Inc. 1%, due 2014 cv. sr. notes (NR) 20,000 249,844 Gilead Sciences, Inc. 1.625%, due 2016 cv. sr. notes (NR) 20 375,000 375,234 Millipore Corp. 3.75%, due 2026 cv. sr. notes (BB-) (3) 750,000 950,625 Mylan Laboratories, Inc. 1.25%, due 2012 cv. sr. notes (BB-) (convertible into Mylan Inc. common stock) 1,500,000 1,522,500 Onyx Pharmaceuticals, Inc. 4%, due 2016 cv. sr. notes (NR) 750,000 759,375 Teva Pharmaceutical Finance Co. B.V. 1.75%, due 2026 cv. sr. deb. (A3) (exchangeable for Teva Pharmaceutical Industries Ltd. ADR) 1,500,000 1,681,875 9,013,203 Real Estate - 3.0% Annaly Capital Management, Inc. 4%, due 2015 cv. sr. notes (NR) 1,250,000 1,310,938 Corporate Office Properties, L.P. 4.25% due 2030 exch. sr. notes (NR) 2,000,000 500,000 Lexington Realty Trust 6%, due 2030 cv. guaranteed notes (NR) 1,000,000 1,041,250 2,852,188 Semiconductors - 2.5% Intel Corp. 2.95%, due 2035 jr. sub. cv. deb. (A-) 900,000 1,071,000 Xilinx, Inc. 2.625%, due 2037 cv. sr. notes (BBB-) (2) 250,000 275,938 2,343,188 Telecommunications - 14.1%	LSB Industries, Inc. 5.5%, due 2012 cv. sr. sub. deb. (NR)	1,250,000	1,256,250
Amylin Pharmaceutical, Inc. 3%, due 2014 cv. sr. notes (NR) 1,000,000 1,073,750 Cephalon, Inc. 2.5%, due 2014 cv. sr. sub. notes (NR) 1,000,000 1,073,750 Endo Pharmaceuticals Holdings, Inc. 1.75%, due 2015 cv. sr. sub. notes (NR) 1,000,000 1,018,750 Gilead Sciences, Inc. 0.5%, due 2011 cv. sr. notes (NR) 500,000 510,000 Gilead Sciences, Inc. 1%, due 2014 cv. sr. notes (NR) 20,000 249,844 Gilead Sciences, Inc. 1.625%, due 2016 cv. sr. notes (NR) 20 375,000 375,234 Millipore Corp. 3.75%, due 2026 cv. sr. notes (BB-) (3) 750,000 950,625 Mylan Laboratories, Inc. 1.25%, due 2012 cv. sr. notes (BB-) (convertible into Mylan Inc. common stock) 1,500,000 1,522,500 Onyx Pharmaceuticals, Inc. 4%, due 2016 cv. sr. notes (NR) 750,000 759,375 Teva Pharmaceutical Finance Co. B.V. 1.75%, due 2026 cv. sr. deb. (A3) (exchangeable for Teva Pharmaceutical Industries Ltd. ADR) 1,500,000 1,681,875 9,013,203 Real Estate - 3.0% Annaly Capital Management, Inc. 4%, due 2015 cv. sr. notes (NR) 1,250,000 1,310,938 Corporate Office Properties, L.P. 4.25% due 2030 exch. sr. notes (NR) 2,000,000 500,000 Lexington Realty Trust 6%, due 2030 cv. guaranteed notes (NR) 1,000,000 1,041,250 2,852,188 Semiconductors - 2.5% Intel Corp. 2.95%, due 2035 jr. sub. cv. deb. (A-) 900,000 1,071,000 Xilinx, Inc. 2.625%, due 2037 cv. sr. notes (BBB-) (2) 250,000 275,938 2,343,188 Telecommunications - 14.1%	Pharmacouticals - 9.6%		
Cephalon, Inc. 2.5%, due 2014 cv. sr. sub. notes (NR)       1,000,000       1,073,750         Endo Pharmaceuticals Holdings, Inc. 1.75%, due 2015 cv. sr. sub. notes (NR)       1,000,000       1,018,750         Gilead Sciences, Inc. 0.5%, due 2011 cv. sr. notes (NR)       500,000       510,000         Gilead Sciences, Inc. 1.6%, due 2014 cv. sr. notes (NR) (2)       250,000       249,844         Gilead Sciences, Inc. 1.625%, due 2016 cv. sr. notes (NR) (2)       375,000       375,234         Millipore Corp. 3.75%, due 2026 cv. sr. notes (BB-) (3)       750,000       950,625         Mylan Laboratories, Inc. 1.25%, due 2012 cv. sr. notes (BB-)       1,500,000       1,522,500         Onyx Pharmaceuticals, Inc. 4%, due 2016 cv. sr. notes (NR)       750,000       759,375         Teva Pharmaceutical Finance Co. B.V. 1.75%, due 2026 cv. sr. deb. (A3)       (exchangeable for Teva Pharmaceutical Industries Ltd. ADR)       1,500,000       1,681,875         Real Estate - 3.0%       Annaly Capital Management, Inc. 4%, due 2015 cv. sr. notes (NR)       1,250,000       1,310,938         Corporate Office Properties, L.P. 4.25% due 2030 exch. sr. notes (NR) (2)       500,000       500,000         Lexington Realty Trust 6%, due 2030 cv. guaranteed notes (NR)       1,000,000       1,041,250         Semiconductors - 2.5%       Intel Corp. 2.95%, due 2035 jr. sub. cv. deb. (A-) (3)       1,000,000       996,250		1 000 000	871 250
Endo Pharmaceuticals Holdings, Inc. 1.75%, due 2015 cv. sr. sub. notes (NR)  Gilead Sciences, Inc. 0.5%, due 2011 cv. sr. notes (NR)  Gilead Sciences, Inc. 1.6, due 2014 cv. sr. notes (NR) (2)  Gilead Sciences, Inc. 1.6, due 2014 cv. sr. notes (NR) (2)  Gilead Sciences, Inc. 1.625%, due 2016 cv. sr. notes (NR) (2)  Millipore Corp. 3.75%, due 2026 cv. sr. notes (BB-) (3)  Mylan Laboratories, Inc. 1.25%, due 2012 cv. sr. notes (BB-)  (convertible into Mylan Inc. common stock)  Onyx Pharmaceuticals, Inc. 4%, due 2016 cv. sr. notes (NR)  Teva Pharmaceutical Finance Co. B.V. 1.75%, due 2026 cv. sr. deb. (A3)  (exchangeable for Teva Pharmaceutical Industries Ltd. ADR)  Real Estate - 3.0%  Annaly Capital Management, Inc. 4%, due 2015 cv. sr. notes (NR)  Corporate Office Properties, L.P. 4.25% due 2030 exch. sr. notes (NR) (2)  Lexington Realty Trust 6%, due 2030 cv. guaranteed notes (NR)  Intel Corp. 2.95%, due 2035 jr. sub. cv. deb. (A-)  Intel Corp. 3.25%, due 2037 cv. sr. notes (BBB-) (2)  Telecommunications - 14.1%			
Gilead Sciences, Inc. 0.5%, due 2011 cv. sr. notes (NR) 500,000 510,000 Gilead Sciences, Inc. 1%, due 2014 cv. sr. notes (NR) (2) 250,000 249,844 Gilead Sciences, Inc. 1.625%, due 2016 cv. sr. notes (NR) (2) 375,000 375,234 Millipore Corp. 3.75%, due 2026 cv. sr. notes (BB-) (3) 750,000 950,625 Mylan Laboratories, Inc. 1.25%, due 2012 cv. sr. notes (BB-) (convertible into Mylan Inc. common stock) 1,500,000 1,522,500 Onyx Pharmaceuticals, Inc. 4%, due 2016 cv. sr. notes (NR) 750,000 759,375 Teva Pharmaceutical Finance Co. B.V. 1.75%, due 2026 cv. sr. deb. (A3) (exchangeable for Teva Pharmaceutical Industries Ltd. ADR) 1,500,000 1,681,875 9,013,203 Real Estate - 3.0% Annaly Capital Management, Inc. 4%, due 2015 cv. sr. notes (NR) 1,250,000 1,310,938 Corporate Office Properties, L.P. 4.25% due 2030 exch. sr. notes (NR) 2 500,000 500,000 Lexington Realty Trust 6%, due 2030 cv. guaranteed notes (NR) 1,000,000 1,041,250 2,852,188 Semiconductors - 2.5% Intel Corp. 2.95%, due 2035 jr. sub. cv. deb. (A-) 900,000 1,071,000 Xilinx, Inc. 2.625%, due 2017 cv. sr. notes (BBB-) (2) 250,000 275,938 2,343,188 Telecommunications - 14.1%	•		
Gilead Sciences, Inc. 1%, due 2014 cv. sr. notes (NR) (2) 250,000 249,844 Gilead Sciences, Inc. 1.625%, due 2016 cv. sr. notes (NR) (2) 375,000 375,234 Millipore Corp. 3.75%, due 2026 cv. sr. notes (BB-) (3) 750,000 950,625 Mylan Laboratories, Inc. 1.25%, due 2012 cv. sr. notes (BB-) (convertible into Mylan Inc. common stock) 1,500,000 1,522,500 Onyx Pharmaceuticals, Inc. 4%, due 2016 cv. sr. notes (NR) 750,000 759,375 Teva Pharmaceutical Finance Co. B.V. 1.75%, due 2026 cv. sr. deb. (A3) (exchangeable for Teva Pharmaceutical Industries Ltd. ADR) 1,500,000 1,681,875 9,013,203  Real Estate - 3.0% Annaly Capital Management, Inc. 4%, due 2015 cv. sr. notes (NR) 1,250,000 1,310,938 Corporate Office Properties, L.P. 4.25% due 2030 exch. sr. notes (NR) (2) 500,000 500,000 Lexington Realty Trust 6%, due 2030 cv. guaranteed notes (NR) 1,000,000 1,041,250 2,852,188  Semiconductors - 2.5% Intel Corp. 2.95%, due 2035 jr. sub. cv. deb. (A-) (3) 1,000,000 996,250 Intel Corp. 3.25%, due 2039 jr. sub. cv. deb. (A-) 900,000 1,071,000 Xilinx, Inc. 2.625%, due 2017 cv. sr. notes (BBB-) (2) 250,000 275,938  Telecommunications - 14.1%			
Gilead Sciences, Inc. 1.625%, due 2016 cv. sr. notes (NR) (2) 375,000 375,234  Millipore Corp. 3.75%, due 2026 cv. sr. notes (BB-) (3) 750,000 950,625  Mylan Laboratories, Inc. 1.25%, due 2012 cv. sr. notes (BB-) (convertible into Mylan Inc. common stock) 1,500,000 1,522,500 Onyx Pharmaceuticals, Inc. 4%, due 2016 cv. sr. notes (NR) 750,000 759,375  Teva Pharmaceutical Finance Co. B.V. 1.75%, due 2026 cv. sr. deb. (A3) (exchangeable for Teva Pharmaceutical Industries Ltd. ADR) 1,500,000 1,681,875 9,013,203  Real Estate - 3.0%  Annaly Capital Management, Inc. 4%, due 2015 cv. sr. notes (NR) 1,250,000 1,310,938 Corporate Office Properties, L.P. 4.25% due 2030 exch. sr. notes (NR) (2) 500,000 500,000  Lexington Realty Trust 6%, due 2030 cv. guaranteed notes (NR) 1,000,000 1,041,250 2,852,188  Semiconductors - 2.5% Intel Corp. 2.95%, due 2035 jr. sub. cv. deb. (A-) (3) 1,000,000 996,250 Intel Corp. 3.25%, due 2039 jr. sub. cv. deb. (A-) 900,000 1,071,000 Xilinx, Inc. 2.625%, due 2017 cv. sr. notes (BBB-) (2) 250,000 275,938 2,343,188  Telecommunications - 14.1%		•	•
Millipore Corp. 3.75%, due 2026 cv. sr. notes (BB-) (3)       750,000       950,625         Mylan Laboratories, Inc. 1.25%, due 2012 cv. sr. notes (BB-)       (convertible into Mylan Inc. common stock)       1,500,000       1,522,500         Onyx Pharmaceuticals, Inc. 4%, due 2016 cv. sr. notes (NR)       750,000       759,375         Teva Pharmaceutical Finance Co. B.V. 1.75%, due 2026 cv. sr. deb. (A3)       (exchangeable for Teva Pharmaceutical Industries Ltd. ADR)       1,500,000       1,681,875         9,013,203         Real Estate - 3.0%         Annaly Capital Management, Inc. 4%, due 2015 cv. sr. notes (NR)       1,250,000       1,310,938         Corporate Office Properties, L.P. 4.25% due 2030 exch. sr. notes (NR) (2)       500,000       500,000         Lexington Realty Trust 6%, due 2030 cv. guaranteed notes (NR)       1,000,000       1,041,250         Semiconductors - 2.5%         Intel Corp. 2.95%, due 2035 jr. sub. cv. deb. (A-) (3)       1,000,000       996,250         Intel Corp. 3.25%, due 2039 jr. sub. cv. deb. (A-)       900,000       1,071,000         Xilinx, Inc. 2.625%, due 2017 cv. sr. notes (BBB-) (2)       250,000       275,938         2,343,188         Telecommunications - 14.1%			
Mylan Laboratories, Inc. 1.25%, due 2012 cv. sr. notes (BB-)       1,500,000       1,522,500         Onyx Pharmaceuticals, Inc. 4%, due 2016 cv. sr. notes (NR)       750,000       759,375         Teva Pharmaceutical Finance Co. B.V. 1.75%, due 2026 cv. sr. deb. (A3)       (exchangeable for Teva Pharmaceutical Industries Ltd. ADR)       1,500,000       1,681,875         (exchangeable for Teva Pharmaceutical Industries Ltd. ADR)       1,500,000       1,681,875         9,013,203         Real Estate - 3.0%         Annaly Capital Management, Inc. 4%, due 2015 cv. sr. notes (NR)       1,250,000       1,310,938         Corporate Office Properties, L.P. 4.25% due 2030 exch. sr. notes (NR) (2)       500,000       500,000         Lexington Realty Trust 6%, due 2030 cv. guaranteed notes (NR)       1,000,000       1,041,250         Semiconductors - 2.5%         Intel Corp. 2.95%, due 2035 jr. sub. cv. deb. (A-) (3)       1,000,000       996,250         Intel Corp. 3.25%, due 2039 jr. sub. cv. deb. (A-)       900,000       1,071,000         Xilinx, Inc. 2.625%, due 2017 cv. sr. notes (BBB-) (2)       250,000       275,938         2,343,188         Telecommunications - 14.1%			
(convertible into Mylan Inc. common stock)       1,500,000       1,522,500         Onyx Pharmaceuticals, Inc. 4%, due 2016 cv. sr. notes (NR)       750,000       759,375         Teva Pharmaceutical Finance Co. B.V. 1.75%, due 2026 cv. sr. deb. (A3)       (exchangeable for Teva Pharmaceutical Industries Ltd. ADR)       1,500,000       1,681,875         Real Estate - 3.0%       9,013,203         Annaly Capital Management, Inc. 4%, due 2015 cv. sr. notes (NR)       1,250,000       1,310,938         Corporate Office Properties, L.P. 4.25% due 2030 exch. sr. notes (NR) (2)       500,000       500,000         Lexington Realty Trust 6%, due 2030 cv. guaranteed notes (NR)       1,000,000       1,041,250         2,852,188         Semiconductors - 2.5%         Intel Corp. 2.95%, due 2035 jr. sub. cv. deb. (A-) (3)       1,000,000       996,250         Intel Corp. 3.25%, due 2039 jr. sub. cv. deb. (A-)       900,000       1,071,000         Xilinx, Inc. 2.625%, due 2017 cv. sr. notes (BBB-) (2)       250,000       275,938         2,343,188         Telecommunications - 14.1%		750,000	<i>750</i> ,02 <i>5</i>
Onyx Pharmaceuticals, Inc. 4%, due 2016 cv. sr. notes (NR)       750,000       759,375         Teva Pharmaceutical Finance Co. B.V. 1.75%, due 2026 cv. sr. deb. (A3)       (exchangeable for Teva Pharmaceutical Industries Ltd. ADR)       1,500,000       1,681,875         Real Estate - 3.0%       9,013,203         Annaly Capital Management, Inc. 4%, due 2015 cv. sr. notes (NR)       1,250,000       1,310,938         Corporate Office Properties, L.P. 4.25% due 2030 exch. sr. notes (NR) (2)       500,000       500,000         Lexington Realty Trust 6%, due 2030 cv. guaranteed notes (NR)       1,000,000       1,041,250         Semiconductors - 2.5%         Intel Corp. 2.95%, due 2035 jr. sub. cv. deb. (A-) (3)       1,000,000       996,250         Intel Corp. 3.25%, due 2039 jr. sub. cv. deb. (A-)       900,000       1,071,000         Xilinx, Inc. 2.625%, due 2017 cv. sr. notes (BBB-) (2)       250,000       275,938         2,343,188    Telecommunications - 14.1%	•	1 500 000	1 522 500
Teva Pharmaceutical Finance Co. B.V. 1.75%, due 2026 cv. sr. deb. (A3)  (exchangeable for Teva Pharmaceutical Industries Ltd. ADR)  1,500,000  1,681,875 9,013,203  Real Estate - 3.0%  Annaly Capital Management, Inc. 4%, due 2015 cv. sr. notes (NR)  1,250,000  1,310,938  Corporate Office Properties, L.P. 4.25% due 2030 exch. sr. notes (NR) (2)  Lexington Realty Trust 6%, due 2030 cv. guaranteed notes (NR)  1,000,000  1,041,250 2,852,188  Semiconductors - 2.5%  Intel Corp. 2.95%, due 2035 jr. sub. cv. deb. (A-) (3)  Intel Corp. 3.25%, due 2039 jr. sub. cv. deb. (A-)  Xilinx, Inc. 2.625%, due 2017 cv. sr. notes (BBB-) (2)  Telecommunications - 14.1%		, ,	, ,
(exchangeable for Teva Pharmaceutical Industries Ltd. ADR)       1,500,000       1,681,875         9,013,203         Real Estate - 3.0%         Annaly Capital Management, Inc. 4%, due 2015 cv. sr. notes (NR)       1,250,000       1,310,938         Corporate Office Properties, L.P. 4.25% due 2030 exch. sr. notes (NR) (2)       500,000       500,000         Lexington Realty Trust 6%, due 2030 cv. guaranteed notes (NR)       1,000,000       1,041,250         Semiconductors - 2.5%         Intel Corp. 2.95%, due 2035 jr. sub. cv. deb. (A-) (3)       1,000,000       996,250         Intel Corp. 3.25%, due 2039 jr. sub. cv. deb. (A-)       900,000       1,071,000         Xilinx, Inc. 2.625%, due 2017 cv. sr. notes (BBB-) (2)       250,000       275,938         Telecommunications - 14.1%	· · · · ·	750,000	137,313
Real Estate - 3.0%  Annaly Capital Management, Inc. 4%, due 2015 cv. sr. notes (NR)  Corporate Office Properties, L.P. 4.25% due 2030 exch. sr. notes (NR) (2) 500,000 500,000  Lexington Realty Trust 6%, due 2030 cv. guaranteed notes (NR) 1,000,000 1,041,250 2,852,188  Semiconductors - 2.5%  Intel Corp. 2.95%, due 2035 jr. sub. cv. deb. (A-) (3) 1,000,000 996,250  Intel Corp. 3.25%, due 2039 jr. sub. cv. deb. (A-) 900,000 1,071,000  Xilinx, Inc. 2.625%, due 2017 cv. sr. notes (BBB-) (2) 250,000 275,938  Telecommunications - 14.1%		1 500 000	1 681 875
Real Estate - 3.0%         Annaly Capital Management, Inc. 4%, due 2015 cv. sr. notes (NR)       1,250,000       1,310,938         Corporate Office Properties, L.P. 4.25% due 2030 exch. sr. notes (NR) (2)       500,000       500,000         Lexington Realty Trust 6%, due 2030 cv. guaranteed notes (NR)       1,000,000       1,041,250         Emiconductors - 2.5%         Intel Corp. 2.95%, due 2035 jr. sub. cv. deb. (A-) (3)       1,000,000       996,250         Intel Corp. 3.25%, due 2039 jr. sub. cv. deb. (A-)       900,000       1,071,000         Xilinx, Inc. 2.625%, due 2017 cv. sr. notes (BBB-) (2)       250,000       275,938         Telecommunications - 14.1%	(cholangeacte for revariatinated that industries Eta. ribit)	1,200,000	
Annaly Capital Management, Inc. 4%, due 2015 cv. sr. notes (NR) 1,250,000 1,310,938 Corporate Office Properties, L.P. 4.25% due 2030 exch. sr. notes (NR) (2) 500,000 500,000 Lexington Realty Trust 6%, due 2030 cv. guaranteed notes (NR) 1,000,000 1,041,250 2,852,188  Semiconductors - 2.5% Intel Corp. 2.95%, due 2035 jr. sub. cv. deb. (A-) (3) 1,000,000 996,250 Intel Corp. 3.25%, due 2039 jr. sub. cv. deb. (A-) 900,000 1,071,000 Xilinx, Inc. 2.625%, due 2017 cv. sr. notes (BBB-) (2) 250,000 275,938  Telecommunications - 14.1%	Real Estate - 3.0%		,,o13, <b>2</b> 03
Corporate Office Properties, L.P. 4.25% due 2030 exch. sr. notes (NR) (2) 500,000 500,000  Lexington Realty Trust 6%, due 2030 cv. guaranteed notes (NR) 1,000,000 1,041,250 2,852,188  Semiconductors - 2.5%  Intel Corp. 2.95%, due 2035 jr. sub. cv. deb. (A-) (3) 1,000,000 996,250  Intel Corp. 3.25%, due 2039 jr. sub. cv. deb. (A-) 900,000 1,071,000  Xilinx, Inc. 2.625%, due 2017 cv. sr. notes (BBB-) (2) 250,000 275,938 2,343,188  Telecommunications - 14.1%		1 250 000	1 310 938
Lexington Realty Trust 6%, due 2030 cv. guaranteed notes (NR)  1,000,000  1,041,250  2,852,188  Semiconductors - 2.5%  Intel Corp. 2.95%, due 2035 jr. sub. cv. deb. (A-) (3)  Intel Corp. 3.25%, due 2039 jr. sub. cv. deb. (A-)  Xilinx, Inc. 2.625%, due 2017 cv. sr. notes (BBB-) (2)  Telecommunications - 14.1%			
2,852,188  Semiconductors - 2.5%  Intel Corp. 2.95%, due 2035 jr. sub. cv. deb. (A-) (3)		·	•
Semiconductors - 2.5%         Intel Corp. 2.95%, due 2035 jr. sub. cv. deb. (A-) (3)       1,000,000       996,250         Intel Corp. 3.25%, due 2039 jr. sub. cv. deb. (A-)       900,000       1,071,000         Xilinx, Inc. 2.625%, due 2017 cv. sr. notes (BBB-) (2)       250,000       275,938         Telecommunications - 14.1%	Zerington round trust one, and Zoe of the guntamood notes (1911)	1,000,000	
Intel Corp. 2.95%, due 2035 jr. sub. cv. deb. (A-) (3)       1,000,000       996,250         Intel Corp. 3.25%, due 2039 jr. sub. cv. deb. (A-)       900,000       1,071,000         Xilinx, Inc. 2.625%, due 2017 cv. sr. notes (BBB-) (2)       250,000       275,938         Telecommunications - 14.1%	Semiconductors - 2.5%		2,002,100
Intel Corp. 3.25%, due 2039 jr. sub. cv. deb. (A-)  Xilinx, Inc. 2.625%, due 2017 cv. sr. notes (BBB-) (2)  Telecommunications - 14.1%  900,000  1,071,000  275,938  2,343,188		1,000,000	996.250
Xilinx, Inc. 2.625%, due 2017 cv. sr. notes (BBB-) (2) 250,000 275,938 2,343,188 <b>Telecommunications - 14.1</b> %	•		•
2,343,188 <b>Telecommunications - 14.1%</b>			
Telecommunications - 14.1%	, (-)	-,	
	<b>Telecommunications - 14.1%</b>		, -,
		1,025,000	1,019,875

Anixter International Inc. 1%, due 2013 cv. sr. notes (BB-)	1,250,000	1,218,750
CommScope, Inc. 3.25%, due 2015 cv. sr. sub. notes (B)	1,000,000	1,013,750
Comtech Telecommunications Corp. 3%, due 2029 cv. sr. notes (NR)	1,000,000	935,000
Equinix, Inc. 2.5%, due 2012 cv. sub. notes (B-)	1,100,000	1,148,125
Equinix, Inc. 4.75%, due 2016 cv. sub. notes (B-)	865,000	1,142,881
Finisar Corp. 5%, due 2029 cv. sr. notes (NR)	250,000	427,813

	Principal	Value
	Amount	(Note 1)
NII Holdings, Inc. 2.75%, due 2025 cv. notes (B-)	1,000,000	1,003,750
NII Holdings, Inc. 3.125%, due 2012 cv. notes (B-)	1,000,000	966,250
SAVVIS, Inc. 3%, due 2012 cv. sr. notes (NR)	2,000,000	1,987,500
SBA Communications Corp. 4%, due 2014 cv. sr. notes (NR)	1,000,000	1,347,500
SBA Communications Corp. 1.875%, due 2013 cv. sr. notes (NR)	500,000	525,625
Telecommunications Systems, Inc. 4.5%, due 2014 cv. sr. notes (NR)	500,000	412,500
		13,149,319
Transportation - 1.7%		
DryShips Inc. 5%, due 2014 cv. sr. notes (NR)	1,000,000	857,500
ExpressJet Holdings, Inc. 11.25%, due 2023 cv. notes (NR)	742,000	753,130
		1,610,630
Travel and Leisure - 1.8%		
MGM Mirage 4.25%, due 2015 cv. sr. notes (Caa1) (2)	1,000,000	895,000
Morgans Hotel Group 2.375%, due 2014 cv. sr. sub. notes (NR)	1,000,000	747,500
	, ,	1,642,500
		, ,
TOTAL CONVERTIBLE BONDS AND NOTES		73,872,095
		, , , , , , , , , , , , , , , , , , , ,
CORPORATE BONDS AND NOTES - 0.4%		
Finance - 0.4%		
Lehman Brothers Holdings Inc. 6%, due 2010 medium-term notes (NR) (4)	50,000	181,000
Lehman Brothers Holdings Inc. 1%, due 2009 medium-term notes (NR) (4)	1,500,000	217,500
		398,500
TOTAL CORPORATE BONDS AND NOTES		398,500
CONVERTIBLE PREFERRED STOCKS - 9.5%		
Automotive - 0.7%		
Ford Motor Company Capital Trust II 6.5% cum. cv. trust pfd. (B3)	15,000	698,100
Banking/Savings and Loan - 4.1%		
Bank of America Corp. 7.25% non-cum. perpetual cv. pfd., series L (Ba3)	1,000	920,000
New York Community Bancorp, Inc. 6% BONUSES units (Baa2)	24,000	1,182,960
Wells Fargo Corp. 7.5% perpetual cv. pfd., series L (Ba1)	1,750	1,706,250
		3,809,210
CONVERTIBLE PREFERRED STOCKS - continued		
Energy - 3.2%		
ATP Oil & Gas Corp. 8% perpetual cv. pfd. (NR)	5,000	276,250
Chesapeake Energy Corp. 5% cum. cv. pfd. (B)	15,000	1,140,000
Chesapeake Energy Corp. 4.5% cum. cv. pfd. (B)	6,360	522,792
Whiting Petroleum Corp. 6.25% perpetual cv. pfd. (B)	5,000	1,070,000
		3,009,042
Foods - 0.7%		
Bunge Limited 4.875% cum. perpetual cv. pfd. (Ba1)	7,500	626,250

Retail - 0.8%		
Amerivon Holdings LLC series A cv. pfd. units (NR)		
(Acquired 04/01/10; Cost \$1,500,000) (2,5,6)	562,695	750,000
TOTAL CONVERTIBLE PREFERRED STOCKS		8,194,502

	Principal Amount	Value (Note 1)
MANDATORY CONVERTIBLE SECURITIES - 7.7% (7)		
Energy - 2.6%		
Apache Corp. 6%, due 8/1/13 mandatory cv. pfd., series D (NR)	10,500	571,725
Great Plains Energy, Inc. 12%, due 6/15/12 equity units (NR) (3)	20,000	1,225,000
Merrill Lynch & Co., Inc. 5.40%, due 9/27/10 PRIDES (A+)	,	, ,
(linked to the performance of ConocoPhillips common stock)	1,000	629,600
		2,426,325
Finance - 1.0%		
Citigroup, Inc. T-DECS 7.5%, due 12/12/12 (NR)	7,500	911,400
Foods - 1.5%		
2009 Dole Food ACES Trust 7%, due 11/1/12 (NR)		
(exchangeable for Dole Food Company, Inc. common stock)	130,000	1,421,875
Home Building - 0.4%		
Beazer Homes USA, Inc. tangible equity units 7.25%, due 8/15/2013 (NR)	17,500	349,825
Metals and Mining - 2.2%		
Vale Capital II 6.75%, due 6/15/12 mandatory cv. notes (BBBH)		
(exchangeable for ADS representing Vale S.A. common stock)	19,200	1,531,008
Vale Capital II 6.75%, due 6/15/12 mandatory cv. notes (BBBH)		
(exchangeable for ADS representing Vale S.A. preferred A shares)	6,500	522,844
		2,053,852
TOTAL MANDATORY CONVERTIBLE SECURITIES (7)		7,163,277
T 4 1 C 49 1 D 1 1 1 1 1 2 2 2 2 2 2		ф <b>л</b> а 0 <b>ла</b> 007
Total Convertible Bonds and Notes - 79.0%		\$73,872,095
Total Corporate Bonds and Notes - 0.4%		398,500
Total Convertible Preferred Stocks - 9.5%		8,892,602
Total Mandatory Convertible Securities - 7.7%		7,163,277
Total Common Stocks - 0.0%		-
Total Investments - 96.5%		90,326,474
Other assets and liabilities, net - 3.5%		3,229,404
Total Net Assets - 100.0%		\$93,555,878

Notes:

- (1) Non-income producing security.
- (2) Security not registered under the Securities Act of 1933, as amended (the "Securities Act") (e.g., the security was purchased in a Rule 144A or a Regulation D transaction). The security may be resold only pursuant to an exemption from registration under the Securities Act, typically to qualified institutional buyers. The Fund generally has no rights to demand registration of such securities. The aggregate market value of these unregistered securities at July 31, 2010 was \$9,765,491 which represented 9.6% of the Fund's net assets.
- (3) Contingent payment debt instrument which accrues contingent interest.

- (4) Security is in default.
- (5) Investment is valued at fair value as determined in good faith pursuant to procedures adopted by the Board of Trustees. It is possible that the estimated value may differ significantly from the amount that might ultimately be realized in the near term, and the difference could be material. The fair value of these securities amounted to \$750,000 at July 31, 2010, which represented 0.7% of the Fund's net assets.

(6) Restricted securities include securities that have not been registered under the Securities Act and securities that are subject to restrictions on resale. The Fund may invest in restricted securities that are consistent with the Fund's investment objective and investment strategies. As of July 31, 2010, the Fund was invested in the following restricted securities:

Amerivon Holdings LLC units containing series A cv. pfd. shares and common equity units, acquired April 1, 2010.

(7) Mandatory Convertible Securities are required to be converted on the dates listed; they generally may be converted prior to these dates at the option of the holder.

**Investment Abbreviations:** 

ACES - Automatic Common Exchange Securities.

ADR - American Depositary Receipts.

ADS - American Depositary Shares.

BONUSES - Bifurcated Option Note Unit Securities.

PRIDES - Preferred Redeemable Increased Dividend Equity Securities.

T-DECS - Tangible Dividend Enhanced Common Stock.

Ratings in parentheses by Moody's Investors Service, Inc. or Standard & Poor's.

NR is used whenever a rating is unavailable.

See accompanying notes.

### Bancroft Fund Ltd. - Selected Notes to Financial Statements (unaudited)

Bancroft Fund Ltd. (the "Fund"), is registered under the Investment Company Act of 1940, as amended, (the "Act") as a diversified, closed-end management investment company.

Security Valuation - Investments in securities traded on a national securities exchange are valued at market using the last reported sales price, supplied by an independent pricing service, as of the close of regular trading. Listed securities, for which no sales were reported, are valued at the mean between closing reported bid and asked prices as of the close of regular trading. Unlisted securities traded in the over-the-counter market are valued using an evaluated quote provided by the independent pricing service, or, if an evaluated quote is unavailable, such securities are valued using prices received from dealers, provided that if the dealer supplies both bid and asked prices, the price to be used is the mean of the bid and asked prices. The independent pricing service derives an evaluated quote by obtaining dealer quotes, analyzing the listed markets, reviewing trade execution data and employing sensitivity analysis. Evaluated quotes may also reflect appropriate factors such as individual characteristics of the issue, communications with broker-dealers, and other market data. Securities for which quotations are not readily available, restricted securities and other assets are valued at fair value as determined in good faith pursuant to procedures adopted by the Board of Trustees. Short-term debt securities with original maturities of 60 days or less are valued at amortized cost.

The Fund has adopted authoritative fair valuation accounting standards which establish an authoritative definition of fair value and set out a hierarchy for measuring fair value. These standards require additional disclosures about the various inputs and valuation techniques used to develop the measurements of fair value and a discussion in changes in valuation techniques and related inputs during the period. These inputs are summarized in the three broad levels listed below:

Level 1 - Quoted unadjusted prices for identical instruments in active markets.

Level 2 - Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-driven valuation in which all significant inputs and significant value drivers are observable in active markets. Level 2 inputs are those in markets for which there are few transactions, the prices are not current, little public information exists or instances where prices vary substantially over time or among brokered market makers, and those received from an independent pricing service.

Level 3 - Model derived valuations in which one or more significant inputs or significant value drivers are unobservable. Unobservable inputs are those inputs that reflect the Fund's own assumptions that market participants would use to price an asset or liability based on the best available information.

The following is a summary of the inputs used to value the net assets of the Fund as of January 31, 2010:

The following is a reconciliation of assets for which level 3 inputs were used in determining value:

The availability of observable inputs can vary from security to security and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of the markets, and other characteristics particular to the security. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in level 3.

Securities Transactions and Related Investment Income - Security transactions are accounted for on the trade date (date the order to buy or sell is executed) with gain or loss on the sale of securities being determined based upon identified cost. Dividend income is recorded on the ex-dividend date and interest income is recorded on the accrual basis, including accretion of discounts and amortization of non-equity premium. For certain securities, known as "contingent payment debt instruments," Federal tax regulations require the Fund to record non-cash, "contingent" interest income in addition to interest income actually received. Contingent interest income amounted to approximately 7 cents per share for the nine months ended July 31, 2010. In addition, Federal tax regulations require the Fund to reclassify realized gains on contingent payment debt instruments to interest income. At July 31, 2010, there were unrealized losses of approximately 10 cents per share on contingent payment debt instruments.

**Federal Income Tax Cost** - At July 31, 2010, the cost basis of investments for federal income tax purposes, as well as the gross unrealized appreciation from investments for those securities having an excess of value over cost, gross unrealized depreciation from investments for those securities having an excess of cost over value and the net unrealized appreciation from investments were \$89,852,770, \$7,872,382, \$(7,398,677) and \$473,705, respectively.

### ITEM 2. CONTROLS AND PROCEDURES.

Conclusions of principal officers concerning controls and procedures.

- (a) The Fund's principal executive officer and principal financial officer have concluded that the Fund's disclosure controls and procedures (as defined in Rule 30a-3(c) under the Act (17 CFR 270.30a-3(c)) are effective as of August 26, 2010 based on the evaluation of these controls and procedures required by Rule 30a-3(b) under the Act (17 CFR 270.30a-3(b)) and Rule 13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934, as amended (17 CFR 240.13a-15(b) or 17 CFR 240.15d-15(b)).
- (b) There have been no changes in the Fund's internal control over financial reporting (as defined in Rule 30a-3(d) under the Act (17 CFR 270.30a-3(d)) that occurred during the Fund's last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Fund's internal control over financial reporting.

#### ITEM 3. EXHIBITS.

Certifications of the principal executive officer and the principal financial officer of the Fund, as required by Rule 30a-2(a) under the Act (17 CFR 270.30a-2(a)), are filed herewith.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.